2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting system
2019
Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal Of Nuclear Cardiology 2019, 27: 1210-1224. PMID: 30868378, DOI: 10.1007/s12350-019-01671-6.Peer-Reviewed Original ResearchConceptsCardiac toxicityPre-clinical cardiotoxicityCardiac magnetic resonanceNuclear cardiologyCardiovascular outcomesNon-invasive imagingCardiovascular toxicityChemotherapeutic agentsCancer treatmentEarly detectionCardiac imagingCancer therapyCancer therapeuticsCardiologyToxicityMagnetic resonanceTreatmentImagingEchocardiographyPatientsCardiotoxicityTherapyCancerSeverityCare